Pharmacoeconomic Evaluation of Cancer Biosimilars Worldwide: A Systematic Review

• Prif Awduron: Hui-Yao Huang (Awdur), Cheng-Cheng Liu (Awdur), Yue Yu (Awdur), Le Wang (Awdur), Da-Wei Wu (Awdur), Lan-Wei Guo (Awdur), Shu-Hang Wang (Awdur), Hong Fang (Awdur), Ying Bai (Awdur), Yuan Fang (Awdur), Qi Fan (Awdur), Chao Sun (Awdur), Ying Wu (Awdur), Ju-Fang Shi (Awdur), Fei Ma (Awdur), Yu Tang (Awdur), Min Dai (Awdur), Ning Li (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: Frontiers Media S.A., 2020-11-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

Background and Purpose: The availability of oncology biosimilars is deemed as a fundamental strategy to achieve sustainable health care. However, there is scarce systematic evidence on economic effectiveness of cancer biosimilars. We aimed to synthesize evidence from pharmacoeconomic evaluation of o...